Processa Pharmaceuticals, Inc.
PCSA
$1.99
-$0.17-7.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -13.44M | -14.11M | -13.56M | -12.93M | -12.88M |
| Total Depreciation and Amortization | 1.20K | 1.20K | 1.20K | 1.20K | 1.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.33M | 538.30K | 633.20K | 982.30K | 831.10K |
| Change in Net Operating Assets | 134.50K | 1.32M | 1.54M | 1.22M | 1.20M |
| Cash from Operations | -11.97M | -12.25M | -11.39M | -10.73M | -10.85M |
| Capital Expenditure | -- | -- | -- | 0.00 | -3.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.16M | -1.35M | -850.00K | -- | -- |
| Cash from Investing | -1.16M | -1.35M | -850.00K | 0.00 | -3.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.80K | -5.10K | -6.60K | -8.10K | -5.70K |
| Issuance of Common Stock | 6.40M | 12.40M | 16.60M | 14.17M | 12.24M |
| Repurchase of Common Stock | -300.00 | -9.30K | -10.40K | -10.70K | -14.40K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.40M | 12.39M | 16.58M | 14.15M | 12.22M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.74M | -1.21M | 4.35M | 3.42M | 1.37M |